Beam Therapeutics Inc. (BEAM)

NMS – Real vaqt narxi. Valyuta: USD

31.58

-0.17 (-0.54%)

Yopilishda: May 12, 2026, 4:00 PM EDT

31.57

-0.01 (-0.03%)

Bozor oldidan: May 13, 2026, 4:01 AM EDT

08.05.2026

BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates

Beam Therapeutics Q1 revenues beat estimates as its gene-editing pipeline advanced, with key updates across the SCD, AATD and PKU programs.

07.05.2026

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates

Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to a loss of $1.24 per share a year ago.

07.05.2026

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg Selected as Optimal Biological Dose; Global Pivotal Cohort Expected to Initiate in Second Half of 2026 Data from Phase 1/2 BEACON Clinical Trial of Risto-cel in Sickle Cell Disease Published in April 1 Issue of the New England Journal of Medicine; U.S. Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Investigational New Drug (IND) Application for BEAM-304 in PKU and Data from BEAM-301 in GSDIa Anticipated in 2026 Ended First Quarter 2026 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into mid-2029 CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported first quarter 2026 financial results and provided updates across the company's hematology and genetic disease franchises.

29.04.2026

Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Ondas Inc (NASDAQ:ONDS) is losing a lot of money and added that he would rather have to find something new and different that is distinct, while he doesn't see anything distinct about Ondas.

27.04.2026

3 Biotech Stocks That Could Benefit from the Patent Cliff

Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.

11.04.2026

Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.

CEO John Evans sold 30,078 company shares for a transaction value of ~$739,000 on April 1, 2026. The sale represented 2.5% of his direct holdings.

01.04.2026

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs)

Videolar

No Data

There is no data to display

Press-relizlar

07.05.2026

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

01.04.2026

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Treatment of SCD with Severe Vaso-occlusive Crises (VOCs)

25.03.2026

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up

24.02.2026

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026

Beam Therapeutics Inc. (BEAM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Beam Therapeutics Inc. (BEAM)

BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth

3 Biotech Stocks That Could Benefit from the Patent Cliff

Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Videolar

No Data

Press-relizlar

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth

3 Biotech Stocks That Could Benefit from the Patent Cliff

Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Videolar

No Data

Press-relizlar

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

Search stocks

Beam Therapeutics Inc. (BEAM)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Beam Therapeutics Inc. (BEAM)

BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth

3 Biotech Stocks That Could Benefit from the Patent Cliff

Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Videolar

No Data

Press-relizlar

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)

BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Jim Cramer: This Tech Stock Is A 'Winner', Snap Does Not Have Growth

3 Biotech Stocks That Could Benefit from the Patent Cliff

Beam Therapeutics' CEO Sold Over 30,000 Company Shares. Here's What This Means for Investors.

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Videolar

No Data

Press-relizlar

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine

Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development

Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)